Gainers
- Arista Networks ANET shares are trading higher after the company reported better-than-expected Q3 EPS and sales results. The company also issued Q4 sales guidance below estimates.
- Halozyme Therapeutics HALO shares are trading higher after the company reported better-than-expected Q3 EPS and sales results. The company also raised FY20 EPS and sales guidance above estimates.
- Inspire Medical Systems INSP shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.
- Jazz Pharmaceuticals JAZZ shares are trading higher after the company reported better-than-expected Q3 EPS and sales results. The company also raised FY20 sales guidance above estimates.
- Karyopharm Therapeutics KPTI shares are trading higher after the company announced the Phase 3 SEAL study met its primary endpoint.
- Medifast MED shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.
- Jakks Pacific JAKK shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.
- Infrastructure And Energy Alternatives IEA shares are trading higher after the company reported a $550 million joint venture with FH Paschen for West Lake Corridor rail expansion in Indiana.
Losers
- SolarEdge Technologies SEDG shares are trading lower after the company reported worse-than-expected Q3 sales results. The company also issued Q4 sales guidance below estimates.
- Enphase Energy ENPH shares are trading lower in sympathy with SolarEdge Technologies after the company reported worse-than-expected Q3 sales results and issued Q4 sales guidance below estimates.
- Coupa Software COUP shares are trading lower after the company announced a proposed public offering of roughly 2.1 million shares of common stock by selling shareholders.
- Pacific Biosciences of California PACB shares are trading lower after the company reported worse-than-expected Q3 EPS results.
- Bruker BRKR shares are trading lower after the company reported Q3 earnings results. It said it expects the pandemic and economic slowdown will continue to have a negative year-over-year impact on its Q4 results.
- Aurinia Pharmaceuticals AUPH shares are trading lower after the company reported its AUDREY trial in dry eye syndrome did not achieve statistical significance on its primary endpoint.
- Durect DRRX shares are trading lower after the company reported worse-than-expected Q3 EPS and sales results.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.